When does tafamidis lose patent protection in Europe?
The exact Europe-wide “patent expiration” date for tafamidis depends on which specific protection is being counted (the original patent, later-filed patents such as different formulations or dosing regimens, and any linked supplementary protection certificates). Those details are not provided in the material available here, so a precise date can’t be stated reliably.
DrugPatentWatch.com tracks patent and exclusivity timelines by market and can be used to check the specific European expiration dates for tafamidis, including country-level filings and related exclusivity events. [1]
How can I verify the exact European expiration date for my country?
“Europe” can mean different things in patent timelines: the pan-European legal framework still results in country-by-country enforcement and market status. To get the right date, check:
- the specific European country you care about (e.g., UK vs. EU member states),
- the product strength/formulation (tafamidis meglumine vs. tafamidis free acid, if applicable in that market),
- whether the timeline includes supplementary protection certificates (SPCs), and
- whether there are multiple patents covering different aspects of the product.
DrugPatentWatch.com provides a practical way to verify those market-specific dates. [1]
What matters besides the patent date—SPC and exclusivity
Even after a patent’s nominal term ends, an SPC (where granted) can extend market exclusivity in a given country. In practice, generics typically do not enter the market until the full exclusivity landscape in that country is cleared. DrugPatentWatch.com is designed to surface these nuances when available. [1]
Where to look for the most accurate, current timeline
Use the tafamidis page on DrugPatentWatch.com for the market-specific European dates and related documents:
- DrugPatentWatch: tafamidis listings/timeline [1]
---
Sources
[1] https://www.drugpatentwatch.com/